Abits
ABTS
Bakkt Holdings
BKKT
Riot Platforms
RIOT
Canaan
CAN
CATHEDRA BITCOIN INC
CBTTF
US Stock MarketDetailed Quotes
THAR Tharimmune
- 2.140
- -0.040-1.83%
Close Dec 13 16:00 ET
- 2.170
- +0.030+1.40%
Post 20:01 ET
3.18MMarket Cap0.04P/E (TTM)
2.190High2.118Low21.27KVolume2.120Open2.180Pre Close45.71KTurnover1.46%Turnover RatioLossP/E (Static)1.49MShares8.55052wk High1.05P/B3.12MFloat Cap1.83552wk Low--Dividend TTM1.46MShs Float1590.000Historical High--Div YieldTTM3.30%Amplitude1.835Historical Low2.148Avg Price1Lot Size
Trending US Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Tharimmune Stock Forum
📊⚡️📊
Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs
Friday, 6th December at 4:15 pm
BRIDGEWATER, NEW JERSEY / ACCESSWIRE / December 6, 2024 / Tharimmune, Inc. (NASDAQ: THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced it has entered into a securities purchase agreement to raise gross proceeds of approximately $2.02 million throug...
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
Tharimmune (NASDAQ:THAR) presented Phase 1 clinical data for TH104 at AASLD The Liver Meeting 2024. The trial evaluated TH104 transmucosal buccal film in patients with chronic liver disease (CLD) for chronic pruritus treatment.
The study showed significant correlation between blood levels and symptom relief, with a correlation coeff...
No comment yet